Gamitrinib TPP
| Code | Size | Price |
|---|
| TAR-T11355-5mg | 5mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Gamitrinib TPP is a mitochondrial targeted HSP90 inhibitor with anti-cancer activity. Gamitrinib TPP is a Gamitrinib (GA) mitochondrial matrix inhibitor.
CAS:
1131626-46-4
Formula:
C52H65N3O8P
Molecular Weight:
891.078
Pathway:
Metabolism; Cytoskeletal Signaling
Purity:
0.98
SMILES:
CO[C@H]1C[C@H](C)CC2=C(NCCCCCC[P+](c3ccccc3)(c3ccccc3)c3ccccc3)C(=O)C=C(NC(=O)C(C)=CC=C[C@H](OC)[C@@H](OC(N)=O)C(C)=C[C@H](C)[C@H]1O)C2=O
Target:
HSP
References
1. Markus D. Siegelin, et al. Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J Clin Invest. 2011 Apr 1; 121(4): 1349?1360.